Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of HY209 in Healthy Male Volunteers
NCT04255979Phase 1Completed
- Sponsor
- Shaperon
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hy209gel in sepsis (6 cohorts), sponsored by Shaperon. Primary endpoint: Incidence of treatment emergent adverse events at Day 6. Started Dec 2019; status: completed.
02
Drugs
hy209gel
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT04255979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04255979.